An Overview of EarlyR Gene Signature in the BIG-198 Trial for Breast Cancer

Video

Steven Buechler, PhD, Department of Applied and Computational Mathematics and Statistics at the University of Notre Dame, discusses independent validation of the EarlyR gene signature in the Breast International Group 1-98 study.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Caregiver & Housing Hurdles: Equity in HCT & CAR T Treatment
Caregiver & Housing Hurdles: Equity in HCT & CAR T Treatment
HCT & CAR T Access: Unseen Barriers & Inequities in Care
HCT & CAR T Access: Unseen Barriers & Inequities in Care
Weiss on How Nanoparticles are Enhancing Radiation Therapy in Lung Cancer
Weiss on How Nanoparticles are Enhancing Radiation Therapy in Lung Cancer
Navigating the Complexities of Immunotherapy in ALL
Navigating the Complexities of Immunotherapy in ALL
First-Line CLL/SLL: Is Chemo-Free the Future?
First-Line CLL/SLL: Is Chemo-Free the Future?
SC Pembrolizumab Noninferior to IV in NSCLC: Phase 3 Trial Results
SC Pembrolizumab Noninferior to IV in NSCLC: Phase 3 Trial Results
Elmariah on the Evolving Role of Fedratinib
Elmariah on the Evolving Role of Fedratinib
Clinical Evaluation of TMLI and PTCy in MRD-Negative AML Transplant
Clinical Evaluation of TMLI and PTCy in MRD-Negative AML Transplant
The Potential of Combination Therapy With Radiopharmaceuticals in Prostate Cancer
The Potential of Combination Therapy With Radiopharmaceuticals in Prostate Cancer
Exploring the Challenges of Radiopharmaceuticals in Prostate Cancer
Exploring the Challenges of Radiopharmaceuticals in Prostate Cancer
Related Content
Exploring HIFU in Early to Intermediate Prostate Cancer Treatment

Exploring HIFU in Early to Intermediate Prostate Cancer Treatment

Jordyn Sava
April 21st 2025
Article

Alexander Kenigsberg, MD, discusses a new nonsurgical, robotic-focused ultrasound procedure for prostate cancer.

Read More

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Jordyn Sava;Aditya Bardia, MD, MPH
February 6th 2025
Podcast

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Leighl Covers PALOMA-3 Trial of SC Amivantamab in NSCLC

Leighl Covers PALOMA-3 Trial of SC Amivantamab in NSCLC

Jordyn Sava
April 18th 2025
Article

Natasha Leighl, MD, MMSc, BSc, discussed key findings from the PALOMA-3 trial for a community oncologist audience.

Read More

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025
Podcast

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

Assessing NCCN Guidelines for Endocrine-Refractory Breast Cancer

Assessing NCCN Guidelines for Endocrine-Refractory Breast Cancer

Targeted Oncology Staff
April 16th 2025
Article

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic breast cancer.

Read More

Participants Discuss PI3K Inhibitors and Endocrine Resistance in Metastatic Breast Cancer

Participants Discuss PI3K Inhibitors and Endocrine Resistance in Metastatic Breast Cancer

Targeted Oncology Staff
April 16th 2025
Article

During a a live event, Virginia Kaklamani, MD, DSc, and participants discussed their experiences using a PI3K/AKT inhibitor in patients with metastatic breast cancer.

Read More